CA2942549A1 - Methods for reducing cardiovascular risk - Google Patents

Methods for reducing cardiovascular risk Download PDF

Info

Publication number
CA2942549A1
CA2942549A1 CA2942549A CA2942549A CA2942549A1 CA 2942549 A1 CA2942549 A1 CA 2942549A1 CA 2942549 A CA2942549 A CA 2942549A CA 2942549 A CA2942549 A CA 2942549A CA 2942549 A1 CA2942549 A1 CA 2942549A1
Authority
CA
Canada
Prior art keywords
antibody
patient
pcsk9
antigen
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2942549A
Other languages
English (en)
French (fr)
Inventor
Laurence BESSAC
Corinne Hanotin
Robert C. Pordy
William J. Sasiela
Gregory G. Schwartz
Philippe Gabriel Steg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CA2942549A1 publication Critical patent/CA2942549A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2942549A 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk Pending CA2942549A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293.1 2015-02-26
EP15305293 2015-02-26
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Publications (1)

Publication Number Publication Date
CA2942549A1 true CA2942549A1 (en) 2015-09-24

Family

ID=52648962

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942549A Pending CA2942549A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Country Status (14)

Country Link
US (2) US20150284473A1 (enExample)
EP (2) EP4403213A3 (enExample)
JP (3) JP2017509624A (enExample)
KR (3) KR20220157516A (enExample)
CN (3) CN114558129A (enExample)
AU (3) AU2015231713B2 (enExample)
CA (1) CA2942549A1 (enExample)
EA (1) EA039310B1 (enExample)
ES (1) ES2978990T3 (enExample)
HU (1) HUE066839T2 (enExample)
IL (1) IL304491B1 (enExample)
MX (1) MX380767B (enExample)
PL (1) PL3119810T3 (enExample)
WO (1) WO2015142668A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117711550A (zh) * 2016-12-20 2024-03-15 阿斯利康(英国)有限公司 用于非处方地分配他汀类药物的系统和方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015289617B2 (en) * 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
IL277127B2 (en) * 2018-03-06 2025-11-01 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
US20220362200A1 (en) * 2018-08-17 2022-11-17 Craig Granowitz Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
TWI887293B (zh) * 2019-11-07 2025-06-21 美商麥迪紐有限責任公司 用於治療心血管疾病之內皮脂酶抗體
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
JP2023501745A (ja) * 2019-11-18 2023-01-18 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体及びその使用
CA3180222A1 (en) * 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2825778A1 (en) * 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117711550A (zh) * 2016-12-20 2024-03-15 阿斯利康(英国)有限公司 用于非处方地分配他汀类药物的系统和方法

Also Published As

Publication number Publication date
KR20160132459A (ko) 2016-11-18
CN114558129A (zh) 2022-05-31
IL304491B1 (en) 2026-07-01
IL304491A (en) 2023-09-01
KR20250006995A (ko) 2025-01-13
JP2022141868A (ja) 2022-09-29
MX2016011975A (es) 2016-12-05
EP4403213A2 (en) 2024-07-24
CN114642661A (zh) 2022-06-21
AU2021201118A1 (en) 2021-03-11
US20220144969A1 (en) 2022-05-12
EA039310B1 (ru) 2022-01-12
ES2978990T3 (es) 2024-09-23
AU2015231713B2 (en) 2020-11-19
KR20220157516A (ko) 2022-11-29
EA201691847A1 (ru) 2017-01-30
CN106794244A (zh) 2017-05-31
AU2024205254A1 (en) 2024-10-03
WO2015142668A1 (en) 2015-09-24
EP4403213A3 (en) 2024-10-23
MX380767B (es) 2025-03-12
JP2024147744A (ja) 2024-10-16
HUE066839T2 (hu) 2024-09-28
EP3119810B1 (en) 2024-02-28
EP3119810C0 (en) 2024-02-28
JP2017509624A (ja) 2017-04-06
US20150284473A1 (en) 2015-10-08
EP3119810A1 (en) 2017-01-25
PL3119810T3 (pl) 2024-07-15
AU2015231713A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US20220144969A1 (en) Methods for reducing cardiovascular risk
US20250059300A1 (en) METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODY
US20200255544A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
US20180296672A1 (en) Methods for Treating Patients with Hypercholesterolemia that is not Adequately Controlled by Moderate-Dose Statin Therapy
EP3337828B1 (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk
HK1232890B (en) Methods for reducing cardiovascular risk
HK1236135B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1236135A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200306

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260312

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260312

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260514